DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1856)

Category

1856 Biopharma Reports

    Long-acting beta2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-...
    Long-acting beta2 agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) have the potential to be first-line chronic obstructive pulmonary disorder (COPD) therapies,......
    The launches of sipuleucel-T (Dendreon’s Provenge) and ipilimumab (Bristol-...
    The launches of sipuleucel-T (Dendreon’s Provenge) and ipilimumab (Bristol-Myers Squibb’s Yervoy) in 2010 and 2011, respectively, represented the first notable immunotherapy approvals in anticancer...
    Major depressive disorder (MDD) continues to be a highly prevalent psychiatric...
    Major depressive disorder (MDD) continues to be a highly prevalent psychiatric disorder. Over 5 million drug-treated MDD patients in the United States fail to respond adequately to treatment with o......
    The market opportunity for hepatitis C virus (HCV) is marked by a large...
    The market opportunity for hepatitis C virus (HCV) is marked by a large prevalent population and high unmet medical need due to the suboptimal tolerability and efficacy of early, interferon-based H......
    The treatment armamentarium for chronic myelogenous leukemia (CML) in Brazil and...
    The treatment armamentarium for chronic myelogenous leukemia (CML) in Brazil and Mexico includes all three currently marketed tyrosine kinase inhibitors (TKIs): Glivec (imatinib,Novartis) for newly......
    1741 - 1760 of 1856